NRIX logo

NRIXNurix Therapeutics Inc

$15.63
$0.33
(2.16%)
Overnight
Updated: 09:12 PM EDT·Prev Close $15.30
EarningsJul 9
Mkt Cap$1.62B
Vol2.54M
News
all
press releases
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?
Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
News Placeholder
More News
News Placeholder
Company News for Jun 9, 2026
Companies In The News Are: CPB, FCEL, NRIX, WIX.
Zacks
News Placeholder
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.
Zacks
News Placeholder
FDA Milestones Fueling Expansion
The biotechnology sector delivered several notable developments. $TNGX, $NTHI, $AIM, $AZN, $NRIX, $NYXH
24-7 Market News
News Placeholder
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market
Nurix Therapeutics and Roche sign a BTK degrader partnership worth up to $2.3 billion, supporting Phase 3 plans for bexobrutideg.read more...
Benzinga
News Placeholder
NRIX Stock Surges Nearly 70% Premarket Today – Roche And Nurix’s Blood Cancer Drug Collaboration Can Tap A $41B Market
The duo will focus on developing and commercializing Nurix’s investigational Bruton’s Tyrosine Kinase degrader, bexobrutideg.
Stocktwits
News Placeholder
Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in pre-market trading. The company recently announced a 1-for-20 reverse stock split.The shares of Marvell Technology Inc (NASDAQ: MRVL) surged in pre-market trading after securing a spot in the S&P 500...
Benzinga
News Placeholder
Roche And Nurix Ink $2.3 Bln Collaboration To Co-Develop BTK Degrader Bexobrutideg
(RTTNews) - Roche (RHHBY) announced it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, Inc. (NRIX). The two companies will co-develop and co-commercialise bexobrutideg (NX-5948), Nurix's investigational Bruton's Tyrosine Kinase (BTK) d...
Nasdaq News: Markets
News Placeholder
Houte Hans Van Sells 14,055 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock
Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 14,055 shares of the company's stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of...
MarketBeat
News Placeholder
Houte Hans Van Sells 2,388 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock
Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 2,388 shares of the company's stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.